BioSpace News Archive

In the October 2 verdict, Circuit Judge Pauline Newman said that promotional materials, press releases, product catalogs, FDA labels and witness testimony did support the “induced infringement” judgement against Teva.

Patients on REYVOW had 3.8-7.2 Times Greater Odds of Achieving Pain Freedom at 2 Hours Versus Placebo in At Least 2 out of 3 Attacks, Resulting in Significant Therapeutic Gains of 10-20%

Xtant Medical Holdings, Inc. announced that it received notification from the NYSE American LLC yesterday that the Company has regained compliance with all of the continued listing standards, including in particular the requirement under NYSE American Company Guide Section 1003 that requires a listed issuer to maintain stockholders’ equity of at least $6 million if it has reported losses from continuing operations, and/or net losses, in its five most recent fiscal years.

Centene Corporation announced it plans to expand its Medicare Advantage offerings for 2021.

New “Made Green to Stay Clean” USP-grade ethanol meets growing consumer demand for sustainably-sourced, low-carbon inputs

Imbio, a leading provider of artificial intelligence solutions for medical imaging analysis, has partnered with Genentech, a member of the Roche Group, to develop quantitative imaging diagnostics for lung diseases.

Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, announced that its data will be featured in oral presentations during the 2020 American Society for Dermatologic Surgery Virtual Annual Meeting, October 9-11, 2020.

Modernizing clinical trial operations is a top priority among life sciences companies according to the Veeva 2020 Unified Clinical Operations Survey Report, one of the largest-ever global surveys of clinical operations professionals.

AVROBIO, Inc. announced that the company has granted non-statutory stock options for the purchase of up to 351,250 shares of the company’s common stock to six new employees as inducement awards under the company’s 2019 Inducement Plan, in accordance with Nasdaq Listing Rule 5635.

Cerevel Therapeutics announced dose administration for the first patient in the Phase 2 REALIZE trial of CVL-865, an orally-administered investigational therapy currently in development as an adjunctive treatment in adults with drug-resistant focal onset seizures, the most prevalent seizure disorder in epilepsy.